Business
Final results for the year ended 31 December 2025
Verici Dx plc reported final results for the year ended December 31, 2025, with total revenues of $3.7 million, comprising $2.9 million from Tutivia sales and $0.8 million from license income, compared to $3.3 million in the prior year. The company completed a $7.9 million net equity fundraise in July 2025 and ended the year with a $3.3 million cash balance, projecting a cash runway to the end of 2026. An adjusted EBITDA loss of $6.2 million was recorded, an increase from $5.4 million in 2024. Significant operational progress included securing Medicare coverage for Tutivia, leading to 1,173 test orders in FY25, a 250% increase from FY24. Post-period, a £2.6 million equity fundraise was completed in June 2026. Disclaimer*
About this update from Verici Dx Plc
[{"type":"text","content":"\n\n\n \nVerici Dx plc\n(\"Verici Dx\" or the \"Company\")\n \nFinal results for the year ended 31 December 2025\n \nVerici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces its audited final results for the year ended 31 December 2025 (\"FY25\"), a year of strong growth and commercial progress for the Company.\n \nFinancial Highlights\n· Total revenues1 of $3.7m (2024: $3.3m) comprising:\no $2.9m recognised revenue from Tutivia sales (2024: $Nil). $3.2m worth of tests were ordered during the year.\no $0.8m from license income (2024: $3.3m), reflecting the expected timing of milestone payments under the outlicensed contract.\n· Equity fundraise of $7.9m (net) completed in July 2025.\n· Cash balance at year-end of $3.3m (2024: $4.1m), slightly ahead of expectations, with $1.5m accounts receivable (2024: $Nil) which, together with the net proceeds of the post period fundraise described below and based on commercial progress continues to support expected cash runway to end of 2026.\n· Adjusted EBITDA2 loss for the year of US$6.2m (2024: US$5.4m).\n· Post-period end: Equity fundraise completed in June 2026 raising gross proceeds of £2.6m.\n \n \nOperational Highlights\n· Significant commercial progress across the year with first revenues from Tutivia™ test results.\n· Secured Medicare coverage for Tutivia™ covering a national estimate of 68% of all US transplant tests and greatly improving patient access.\n· Receipt of milestone payment of $0.8m from Thermo Fisher Scientific for the product licensing of PTRA (Clarava).\n· Continued increase in test adoption with:\no 1,173 Tutivia™ tests ordered in FY25 (FY24: 334), up c. 250% from the previous year.\no Saw a strong acceleration in the Tutivia™ testing order rate of 296 tests in Q4 25, a 68% increase over the previous quarter (Q4 24) and compares favourably to a total test ordering figure of 334 for the whole of FY 2024.\n· Increased adoption of of TutiviaTM, now used in centres representing 20% of annual kidney transplants in the US.\n· Provider Participation Agreement signed with Pr...